Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase producing enterobacteriaceae

• Clinical or microbiological failure did not occur in patients receiving cefepime.• Cefepime may be a favorable alternative in ESBL infections such as UTIs.• Role of cefepime as a carbapenem-sparing agent should be further explored.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Short Communication Source Type: research